About US
Contact us
-
Brussels aims to attract UK pharma business post-BrexitThe Brussels Capital Region has launched a major campaign to attract UK-based pharmaceutical and life sciences organisations after Brexit. Pharmaceutical businesses based in the British region will r2019/3/13
-
GeNeuro announces positive results from two-year study of MS drugSwiss biopharma company GeNeuro has announced tgat its two-year Phase IIb study of temelimab in multiple sclerosis (MS) confirmed the results from a previous 48-week CHANGE-MS trial where the drug ha2019/3/12
-
UK prioritises transport of medical products in no-deal Brexit scenarioDespite continued attempts to reach a deal acceptable to Parliament in order for the UK to leave the European Union (EU) with a deal on 29 March, various UK Government departments have listed critica2019/3/12
-
Now that Lilly has a cheaper generic Humalog, will Novo Nordisk and Sanofi follow?Caught by an outcry over high insulin prices, Eli Lilly recently unveiled anauthorized generic version of its Humalog insulin at half the price of the original brand. Now the question is: Will Sanofi2019/3/11
-
Allergan activists, ready for 'disruptive action,' call for split, sale, executive changesAfter Allergan revealed Wednesday that a major pipeline prospect had flunked a phase 3 trial, analysts predicted activist investors demanding change would ratchet up pressure on the company’s executi2019/3/11
-
Name of Amazon-JPMorgan-Berkshire Hathaway joint venture announcedAmazon has announced its joint venture with Berkshire Hathaway and JPMorgan Chase will be named Haven. The company, which is headquartered in Boston with another office in New York, launched its webs2019/3/8
-
Beam Therapeutics raises $135m to advance CRISPR technologiesUS-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies. The company also intends2019/3/8
-
Celgene’s fedratinib gets FDA priority review for myelofibrosisCelgene has secured the US Food and Drug Administration (FDA) priority review status for the new drug application (NDA) of fedratinib to treat patients with myelofibrosis. Myelofibrosis is a serious2019/3/7
-
BeiGene and Ambrx form R&D alliance for new biologicsChina-based immuno-oncology drugs maker BeiGene and American biopharmaceutical firm Ambrx have formed a research and development (R&D) partnership to develop next-generation biologic drugs. The w2019/3/7
-
Vertex reports preliminary data for triple combination cystic fibrosis therapyBoston-based pharmaceutical company Vertex has published promising interim analysis from two Phase III studies of a triple combination therapy of VX-445, tezacaftor and ivacaftor for cystic fibrosis.2019/3/6